Updated Meta-Analysis Excluding a Retracted Trial

Category	Detail
Condition	Time-of-day immunotherapy administration and outcomes in advanced cancers
Key Mechanisms	The article reports pooled associations between immunotherapy administration time and overall and progression-free survival; it does not describe biological mechanisms.
Target Population	Patients with advanced cancers represented in 28 studies, totaling 5,919 participants.
Care Setting	Evidence synthesis of clinical studies; the source does not specify a care setting.

The LungTIME-C01 randomized clinical trial was retracted after publication of the original meta-analysis and was excluded from the revised analysis.
The revised analysis included 28 studies and 5,919 patients, compared with 29 studies and 6,129 patients originally.
The revised pooled hazard ratio for overall survival was 0.61 (95% CI, 0.52-0.71); the original estimate was 0.60 (95% CI, 0.51-0.70).
The revised pooled hazard ratio for progression-free survival was 0.65 (95% CI, 0.57-0.74); the original estimate was 0.62 (95% CI, 0.54-0.71).
The repeat analyses retained the original statistical methods, including primary and subgroup analyses, sensitivity analyses, and assessments of heterogeneity and publication bias.

The source reports that the LungTIME-C01 trial was retracted and excluded; it does not provide clinical risk guidance.

The revised meta-analysis included 5,919 patients across 28 studies of time-of-day immunotherapy administration in advanced cancers.

The article reports pooled survival estimates but provides no prescribing instructions or patient-level treatment recommendations.

Clinical Scorecard: Updated Meta-Analysis Excluding a Retracted Trial